Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles

References

• Abou el Ela AESF, Hassan MA, El-Maraghy DA. 2014. Ketorolac tromethamine floating beads for oral application: characterization and in vitro/in vivo evaluation. Saudi Pharm J. 22:349–359.
   PubMed Web of Science ®Google Scholar
• Asadi A. 2014. Streptomycin-loaded PLGA-alginate nanoparticles: preparation, characterization, and assessment. Appl. Nanosci. 4:455–460.
   Web of Science ®Google Scholar
• Betancourt T, Brown B, Brannon-Peppas L. 2007. Doxorubicin- loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2:219–232.
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. 2001. A randomized double-blind study of risperidone and Olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 158:765–774.
   PubMed Web of Science ®Google Scholar
• Gasco MR. 1993. Methods for producing solid lipid microparticles having a narrow size distribution. United States Patents, USS 188837.
   Google Scholar
• Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. 1999. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 57:171–185.
   PubMed Web of Science ®Google Scholar
• Heiati H, Phillips NC, Tawashi R. 1996. Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res. 13:1406–1410.
   PubMed Web of Science ®Google Scholar
• Kashi TSJ, Eskandarion S, Esfandyari-Manesh M, Marashi SMA, Samadi N, Fatemi SM, et al. 2012. Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Int J Nanomed. 7:221–234.
   PubMed Web of Science ®Google Scholar
• Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. 2001. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 21:389–397.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mehnert W, Lucks JS, Schwarz C, zur Mühlen A, Weyhers H, Freitas C, Rühl D. 1995. Solid lipid nanopaticles (SLN) – an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 41:62–69.
   Web of Science ®Google Scholar
• Özbaßs-Turan S, Akbugă J. 2011. Plasmid DNA-loaded chitosan/TPP nanoparticles for topical gene delivery. Drug Deliv. 18:215–222.
   PubMed Web of Science ®Google Scholar
• Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, et al. 2001. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol. 16:331–337.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W, Lucks JS, Muller RH. 1994. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control Release. 30:83–96.
   Web of Science ®Google Scholar
• Seju U, Kumar A, Sawant KK. 2011. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 7:4169–4176.
   PubMed Web of Science ®Google Scholar
• Sjostrom B, Bergenstahl B. 1992. Preparation of submicron drug particles in lecithin-stabilized w/o emulsions: I. Model studies of the precipitation of cholesteryl acetate. Int J Pharm. 88:53–62.
   Web of Science ®Google Scholar
• Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. 2008. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 69:445–453.
   PubMed Web of Science ®Google Scholar
• Westesen K, Bunjes H, Koch MHJ. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of drug loading capacity and sustained release potential. J Control Release. 48:223–236.
   Web of Science ®Google Scholar
• Zur Muhlen A, Schwarz C, Mehenert W. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanisms. Eur J Pharm Biopharm. 45:149–155.
   PubMed Web of Science ®Google Scholar